Drägerwerk AG & Co KGaA

Silver lining beyond the soft Q124 headline figures

16/04/24 -"Drägerwerk reported softer-than-expected Q1 24 numbers, with sales declining by 2.6%. As expected, growth in the safety segment partly offset the decline in the medical business. However, we view the ..."

PDF page sample
Pages
46
Language
English
Published on
16/04/24
Download
You may also be interested by these reports :
01/05/24
Drägerwerk reported Q1 24 numbers which were bang in-line with the prelims. Sales were down with the expected segmental trends. However, with a ...
30/04/24
The drop in our DCF valuation is largely a reflection of the double digit earnings cut for the next two forecast years, as we re-phase the delivery ...
30/04/24
Qiagen started 2024 on a decent note with the operating performance in line with the street’s expectations but above the management’s guidance. As ...
29/04/24
While our earnings estimates have reset higher, the extent of the upgrade is limited compared with the fundamental metrics (DCF and NAV) given that ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO